Abeona Therapeutics Inc vs Baidu Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Baidu Inc trades at $104.84 (market cap $36.18B). The key difference: Baidu Inc is far larger — about 85.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Baidu Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | BIDU | |
|---|---|---|
Market Cap | $421.19M | $36.18B |
Sector | Health | Media |
52-Week High | $7.45 | $162.52 |
52-Week Low | $4.17 | $86.76 |
Enterprise Value | $276.10M | $32.81B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
Baidu (BIDU) trades at $104.41, down 4.65% today amid broader pressure on Chinese stocks. The stock shows a bearish technical signal, with recent earnings missing expectations in Q1 2026. Revenue declined to $129.08B in 2025, and net income margin compressed to 1.02%. However, analyst consensus remains strongly bullish with a $169.80 price target, and the company is advancing AI initiatives, including autonomous vehicle testing in London.
The outlook is mixed: strong analyst support and AI growth potential offer upside, but weak profitability, declining revenue, and macroeconomic risks in China pose significant challenges. Investors should weigh the high P/E of 78.19 against future AI-driven earnings acceleration.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →